Clinical trial
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies…
NCT00327093 · Hospices Civils de Lyon, Other · Terminated
Key facts
| NCT number | NCT00327093 |
|---|---|
| Title | Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases |
| Official title | Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases |
| Lead sponsor | Hospices Civils de Lyon, Other |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | cetuximab, bevacizumab |
| Enrollment | 31 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | May 18, 2006 |
| Last update posted | Feb 9, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: